Boston Scientific Corporation (NYSE:BSX) reported upbeat earnings for the fourth quarter on Wednesday.The company posted fourth-quarter 2025 revenues of $5.29 billion on Wednesday, almost in line with the consensus estimate of $5.28 billion, beating the management guidance of $5.22 billion-$5.31 billion. The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 78 cents and the management guidance of 77-79 cents.Boston Scientific forecasts net sales growth of approximatel ...

With a market cap of around $132 billion, Medtronic plc (MDT) is a global medical technology company that develops, manufactures, and sells device-based therapies to healthcare providers and patients worldwide. It operates across cardiovascular, neuroscience, medical-surgical, and diabetes care, offering innovative solutions that address a wide range of chronic and acute conditions. Shares of the Galway, Ireland-based company have lagged behind the broader market over the past 52 weeks. MDT stock has inc ...

近日，嘉兴长创天使创业投资合伙企业（有限合伙）（以下简称天使基金），现面向全国优秀机 构，公开遴选子基金管理机构，有关事项公告如下： 天使基金目标总规模10亿元，由嘉兴市政府股权投资基金有限公司、嘉兴市人才投资服务有限公 司等出资设立，注册于嘉兴市，管理人为嘉兴长三角创新投资集团有限公司下属嘉兴长投创业投资 有限公司（以下简称长投投资）。 子基金原则上采取有限合伙制，规模原则上不低于1亿元；天使基金对子基金的出资比例不超过子 基金规模的40%。天使基金投向天使类企业的比例不低于该基金规模的50%，天使子基金应重点 支持人工智能、医药科技、新材料、量子科技、消费科技等产业领域。 来源：嘉兴长投创业投资有限公司 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 热文： 投资人"忙疯了" 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ ...

Tactile Systems Technology, Inc. (TCMD) Investment Analysis TCMD's recent stock price decline of approximately 4.22% over the past 30 days and 5.25% in the last 10 days may present a buying opportunity for investors. The company has a Piotroski Score of 8, indicating strong financial health and robust fundamentals. Analysts have set a target price of $32.50 for TCMD, suggesting significant growth potential and making it an attractive investment option.Tactile Systems Technology, Inc. (NASDAQ: TCMD) is a med ...

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong second-quarter fiscal 2026 performance and ongoing studies [1][2] Financial Performance - AngioDynamics reported a revenue increase of 8.8% year over year to $79.4 million in fiscal Q2 2026, with the NanoKnife revenue rising 22.2% due to record prostate cancer procedure volumes [7][10] - The Auryon franchise generated $16.3 million in revenue, reflecting an 18.6% year-over-year growth, marking 18 consecutive quarters of double-digit growth [5][10] - The company has a market capitalization of $422.1 million and projects a 51.9% growth over the next year [2] Growth Drivers - The NanoKnife franchise is a key growth driver, with probe sales increasing 14.4% year over year, attributed to rising adoption in prostate cancer procedures [3][4] - Management noted steady adoption of NanoKnife, supported by procedural growth and increasing clinical utilization, particularly in the prostate cancer market [4] - The mechanical thrombectomy portfolio saw a revenue increase of 3.9% year over year to $11 million, with AlphaVac achieving over 40% growth [9] Market Position and Trends - AngioDynamics has gained 9.8% in share price over the last six months, outperforming the industry growth of 5.2% and the S&P 500's increase of 11.9% [1] - The company has been experiencing a positive estimate revision trend, with the Zacks Consensus Estimate for loss narrowing to 27 cents per share for fiscal 2026 [13] Challenges - Management acknowledged ongoing tariff-related costs of $4–$6 million for the fiscal year, which may pose a structural margin headwind [11][12]

Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Karim Boussebaa as Chief Executive Officer of the Group. Meeting today, Guerbet’s Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Mr. Karim Boussebaa as Chief Executive Officer. This appointment will take effect on ...

Core Insights - The U.S. FDA has granted 510(k) clearance for Becton, Dickinson and Company's new breast biopsy system, the EnCor EnCompass, expected to launch in early 2026 [1][2] Product Overview - The EnCor EnCompass system features advanced capabilities such as high and low vacuum strengths, 360-degree sampling ability, and customizable probes for different lesion types [2] Market Valuation and Performance - Becton, Dickinson maintains a market capitalization of $59.10 billion, with a 52-week stock price range of $162.29 to $251.99 [3] - The stock is currently up 0.25% at $207.90, aligning with broader market gains, as the S&P 500 is up 0.50% [3][10] Earnings Forecast and Analyst Ratings - Analysts forecast earnings per share of $2.82, down from $3.43 in the same quarter last year, and revenue of $5.15 billion, slightly down from $5.17 billion [4] - The consensus rating among analysts is "Buy," with an average price target of $245.93, indicating the stock may be trading at a premium [4] Technical Analysis - The Relative Strength Index (RSI) is at 66.21, indicating neutral to bullish momentum [7] - The MACD shows bullish momentum with a value of 2.94, indicating the MACD line is above the signal line [7] - Key support level is at $188.50 and resistance level is at $208 [7] Momentum and Value Assessment - The Benzinga Edge score indicates a "High-Flyer" setup, with a momentum score of 35.35 confirming positive trends, but a low value score of 24.16 suggests the stock is priced for perfection [5][8] ETF Impact - Becton, Dickinson has notable weights in key ETFs, including T. Rowe Price Capital Appreciation Equity ETF (2.94%), iShares US Medical Devices ETF (4.44%), and Kovitz Core Equity ETF (4.20%) [9]

Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

国家药监局召开脑机接口医疗器械工作推进会。会议要求，要坚持安全有效为首要前提，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床。 ...

Core Insights - Picard Medical, Inc. successfully completed its initial public offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds, which will be used to strengthen its balance sheet and accelerate research and development [4][7]. Financial Performance - Third quarter revenue reached $1.19 million, a 35% increase from the same period in 2024, driven by higher U.S. product sales and increased driver rentals [5]. - The cost of revenue declined by 15% year-over-year, resulting in a gross loss reduction of 81% to $0.13 million [5]. - Operating expenses decreased by 11% to $3.36 million, leading to a narrowed operating loss of $3.36 million compared to $3.77 million in Q3 2024 [6]. - For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, an 11% increase from 2024, while the operating loss remained consistent at $10.3 million [7]. Strategic Developments - The company secured additional patent protection for its SynCardia Total Artificial Heart (STAH), reinforcing its commitment to life-saving technology [3]. - Two independent directors, Sam Van and George Ye, were appointed to the board to provide leadership and guidance as the company transitions to a public entity [3][7]. - A new patent (U.S. Patent No. 12,383,722 B2) was granted for the next-generation fully implantable SynCardia Total Artificial Heart, expanding the company's intellectual property portfolio [7]. Market Position - Picard Medical, through its subsidiary SynCardia, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, with over 2,100 implants performed globally [10].